Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — Quidel — Merger or Acquisition (December 2021)
15 slides from Quidelortho's merger presentation, Dec 23, 2021
Slide 1: Quidel Corporation's Acquisition of Ortho Clinical Diagnostics
Quidel Corporation’s Acquisition of Ortho Clinical Diagnostics Investor Conference Call December 23, 2021 Copyright © 2021 Quidel Corporation. All rights reserved.
Slide 2: Forward-Looking Statements and Additional Information
Forward-Looking Statements and Additional Information NO OFFER OR SOLICITATION The information in this communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote or
Slide 3: Compelling Strategic Rationale and Value Creation Opportunity
Compelling Strategic Rationale and Value Creation Opportunity • Innovative solutions spanning the diagnostics continuum – high- $50B Definitive volume to rapid point-of-care and home use Combined Market Leadership • Multiple modalities to address increasingly diverse clinical and Opportunity custome
Slide 4: Transaction Overview
Transaction Overview • Quidel to acquire Ortho for $24.68 per share of common stock, funded through a combination of cash and newly issued shares in the combined company Transaction • Total equity value of ~$6.0 billion Details • Ortho shareholders will receive $7.14 per common share and 0.1055 shar
Slide 5: Ortho Clinical Diagnostics Business Overview
Ortho Clinical Diagnostics Business Overview Leading In Vitro Diagnostics Pure-play Revenue by Business Segment(2) ($ in millions) • Rich 80+ year history of leadership in mid- and high-volume Non-Core testing 2% • A global leader in screening and diagnosis across clinical chemistry, immunoassay and
Slide 6: Enhances Quidel's Ability to Address Key Market Trends
Enhances Quidel’s Ability to Address Key Market Trends Trends Implications Rising demand of diagnostic Decentralization of care testing: 1 and testing • Manage chronic conditions • New diagnostic tests to support recently discovered markers Emergence of new • Repeated therapy monitoring 2 treatments
Slide 7: Leadership Across Large and Growing Market Opportunities
Leadership Across Large and Growing Market Opportunities Total Addressable Market: $50 Billion Point-of-care Clinical Laboratories Transfusion Medicine Market Leader in Respiratory Market Leader in acute care and Global Leader in Rapid Testing “STAT” Labs Immunohematology Sofia® Savanna® VITROS® Aut
Slide 8: Multiple Drivers for Clear Ongoing Value Creation
Multiple Drivers for Clear Ongoing Value Creation Stronger financial profile Enhanced R&D • Durable business model • Significant cost Commercial • Capabilities of and revenue leverage synergies both Broad organizations • Greater financial portfolio • Menu expansion flexibility for • Global footprint
Slide 9: Point-of-Care Capabilities Spanning Key Setting and Critical Indications
Capabilities Spanning Key Setting and Critical Indications Clinical Setting Disease Indication Point-of-Care Decentralized Settings • Infectious Disease At-Home / At-Home / • Cardiac Over The Therapeutic “PhAST” Counter Monitoring • Sepsis • Clinical Chemistry Clinics • Special Chemistry Freestandin
Slide 10: Global Footprint Provides Channel to Accelerate Compelling Product Portfolio
Global Footprint Provides Channel to Accelerate Compelling Product Portfolio Galway, Ireland Prague, Czech Republic Pencoed, Wales Rochester, NY Strasbourg, France Kornwestheim, Germany Athens, OH Beverly, MA San Diego, CA Waltham, MA Tokyo, Japan Shanghai, China Quidel / Ortho Sales Presence Mexico
Slide 11: Complementary Offerings to Reference Labs, Hospitals, Clinics, & At-Home Testing
Complementary Offerings to Reference Labs, Hospitals, Clinics, & At-Home Testing Research Reference Labs Hospitals Clinics Home • Pharma CRO Univ. • LabCorp, Quest, ARUP, etc. • Large Hospitals Lab • Free-Standing ER • Public Health Clinic • OTC and Self-Testing • Public Health • Small Hospitals Lab
Slide 12: Further Diversifies Quidel's Footprint and Revenue Streams
Further Diversifies Quidel’s Footprint and Revenue Streams Quidel Pro Forma $1.9B $2.0B $3.9B TTM Q3’21 Revenue TTM Q3’21 Revenue TTM Q3’21 Revenue RoW China 5% 3% EMEA Other Other 4% 13% 21% Revenue China 8% North by China America EMEA 9% 13% 53% Geography North North America America EMEA 70% 88% 1
Slide 13: Addition of Ortho Creates a Leading Top-7 IVD Pure-Play
Addition of Ortho Creates a Leading Top-7 IVD Pure-Play FY 2020 Revenue ($ in millions) (1) $15,431 (1) $10,805 Top-7 (1) $7,403 Diagnostics Player (2) $5,343 (1) $4,989 $3,809 100,000+ Quidel Pro Forma $3,428 Instrument Installed Base $2,728 Across All Platforms (1) $2,500 (1) $2,068 130+ $1,766 $1
Slide 14: Compelling Strategic Rationale and Value Creation Opportunity
Compelling Strategic Rationale and Value Creation Opportunity • Innovative solutions spanning the diagnostics continuum – high- $50B Definitive volume to rapid point-of-care and home use Combined Market Leadership • Multiple modalities to address increasingly diverse clinical and Opportunity custome
Slide 15: a) |
a) |